X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (368) 368
Publication (30) 30
Book Review (25) 25
Conference Proceeding (18) 18
Book Chapter (12) 12
Web Resource (3) 3
Book / eBook (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (211) 211
humans (200) 200
cardiac & cardiovascular systems (164) 164
male (155) 155
female (152) 152
abridged index medicus (138) 138
middle aged (136) 136
aged (132) 132
acute coronary syndromes (100) 100
heart attacks (87) 87
treatment outcome (84) 84
drug therapy (68) 68
risk factors (67) 67
cardiovascular (66) 66
clopidogrel (59) 59
platelet aggregation inhibitors - therapeutic use (59) 59
ticlopidine - analogs & derivatives (58) 58
mortality (57) 57
myocardial infarction (54) 54
double-blind method (53) 53
heart attack (52) 52
peripheral vascular disease (51) 51
myocardial infarction - drug therapy (49) 49
care and treatment (47) 47
acute coronary syndrome - drug therapy (46) 46
medicine, general & internal (45) 45
prasugrel hydrochloride (44) 44
percutaneous coronary intervention (42) 42
aspirin (41) 41
coronary heart disease (41) 41
cardiovascular disease (39) 39
patient outcomes (39) 39
ticlopidine - therapeutic use (39) 39
cardiac patients (38) 38
clinical trials (38) 38
myocardial infarction - mortality (38) 38
acute coronary syndrome (37) 37
cardiovascular diseases (37) 37
internal medicine (37) 37
myocardial-infarction (36) 36
follow-up studies (35) 35
time factors (35) 35
cardiology (33) 33
drug therapy, combination (33) 33
electrocardiography (33) 33
platelet aggregation inhibitors - administration & dosage (32) 32
piperazines - therapeutic use (31) 31
risk (31) 31
thiophenes - therapeutic use (31) 31
usage (31) 31
outcomes (30) 30
thrombosis (30) 30
patients (29) 29
prasugrel (29) 29
stroke (29) 29
clinical outcomes (28) 28
antiplatelet therapy (27) 27
dose-response relationship, drug (27) 27
hemorrhage - chemically induced (27) 27
registries (27) 27
blood platelets (26) 26
prevention (26) 26
artery-disease (25) 25
diabetes (25) 25
dosage and administration (25) 25
hematology (25) 25
research (25) 25
cardiology and cardiovascular medicine (24) 24
coronary vessels (24) 24
intervention (24) 24
ticlopidine - administration & dosage (24) 24
unstable angina (24) 24
cholesterol (23) 23
health aspects (23) 23
heart failure (23) 23
analysis (22) 22
myocardial infarction - therapy (22) 22
platelet aggregation inhibitors - adverse effects (22) 22
risk assessment (22) 22
stent thrombosis (22) 22
trial (22) 22
adult (21) 21
aged, 80 and over (21) 21
metaanalysis (21) 21
myocardial infarction - prevention & control (20) 20
safety (20) 20
stents (20) 20
thiophenes - administration & dosage (20) 20
acute coronary syndrome - therapy (19) 19
aspirin - therapeutic use (19) 19
diabetes mellitus (19) 19
incidence (19) 19
myocardial infarction - epidemiology (19) 19
prognosis (19) 19
angioplasty (18) 18
angioplasty, balloon, coronary (18) 18
anticoagulants (18) 18
cerebral infarction (18) 18
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (18) 18
kaplan-meier estimate (18) 18
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2009, 1, American Heart Association clinical series, ISBN 1405176261, xiv, 289
Stephen D. Wiviott, MD., Investigator TIMI Study Group, Associate Physician, Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School,... 
Cardiology | Medical | Blood platelets | Myocardial Ischemia - blood | Platelet Aggregation Inhibitors | Coronary heart disease - Chemotherapy | Blood platelets - Aggregation | Myocardial Ischemia | Coronary heart disease | Myocardial Ischemia - drug therapy
Book
The Lancet, ISSN 0140-6736, 08/2019, Volume 394, Issue 10198, pp. 560 - 561
[...]the oral administration of SGLT2i is patient-friendly and the safety profile is, in general, favourable. In terms of more detailed data on the prevention... 
Heart failure | Heart | Medical research | Diabetes mellitus | Oral administration | Health risks | Clinical trials | Risk reduction | Patients | Diabetes | Cardiology | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Heart diseases | Failure | Ejection | Index Medicus | Abridged Index Medicus
Journal Article
02/2009, American Heart Association Clinical Ser., ISBN 9781444303339
Annotation Draws from expertise of leaders in antiplatelet therapy Easytouse layout enables rapid browsing Edited by a member of the prestigious TIMI study... 
Coronary Heart Disease | Blood Platelets | Medical
Web Resource
Diabetes, ISSN 0012-1797, 06/2019, Volume 68, Issue Supplement 1, p. 236
Background: DECLARE-TIMI 58 showed that dapagliflozin (dapa) a sodium glucose co-transporter 2 inhibitor (SGLT2i), reduced the rate of cardiovascular death or... 
Glucose transporter | Creatinine | End-stage renal disease | Renal function | Kidneys | Epidermal growth factor receptors | Diabetes mellitus | Sodium | Arteriosclerosis | Death | Kidney diseases | Diabetes | Cardiovascular diseases | Heart diseases | Kidney transplantation
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2017, Volume 376, Issue 18, pp. 1713 - 1722
Journal Article
JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2015, Volume 65, Issue 20, pp. 2211 - 2221
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2015, Volume 372, Issue 19, pp. 1791 - 1800
Patients with myocardial infarction 1 to 3 years previously were assigned to ticagrelor, 90 or 60 mg twice daily, or to placebo, in addition to low-dose... 
MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | CLOPIDOGREL | MANAGEMENT | ESC GUIDELINES | AMERICAN-COLLEGE | PREVENTION | ASSOCIATION TASK-FORCE | ACUTE CORONARY SYNDROMES | PRASUGREL | ASPIRIN | Purinergic P2Y Receptor Antagonists - administration & dosage | Double-Blind Method | Drug Administration Schedule | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Risk | Secondary Prevention | Adenosine - administration & dosage | Aspirin - administration & dosage | Purinergic P2Y Receptor Antagonists - adverse effects | Myocardial Infarction - drug therapy | Adenosine - adverse effects | Adenosine - analogs & derivatives | Intracranial Hemorrhages - chemically induced | Platelet Aggregation Inhibitors - administration & dosage | Cardiovascular Diseases - mortality | Female | Aged | Hemorrhage - chemically induced | Drug Therapy, Combination | Platelet Aggregation Inhibitors - adverse effects | Dose-response relationship (Biochemistry) | Treatment outcome | Care and treatment | Safety and security measures | Analysis | Dosage and administration | Ticagrelor | Heart attack | Risk factors | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Heart attacks | Hemorrhage | Long term | Patients | Thrombolysis | Bleeding | Blood platelets | Antagonist drugs | Cardiovascular diseases | Drug therapy | Index Medicus | Abridged Index Medicus | Life Sciences | Human health and pathology
Journal Article